化疗诱导的非小细胞肺癌免疫调节：联合化疗免疫疗法的理论依据
Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
作者信息
Zheng Hua, Zeltsman Masha, Zauderer Marjorie G, Eguchi Takashi, Vaghjiani Raj G, Adusumilli Prasad S
机构信息
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY, USA.
Department of Oncology, Beijing Chest Hospital, Capital Medical University, 97 Machang, Tongzhou District, Beijing, China.
出版信息
Immunotherapy. 2017 Sep;9(11):913-927. doi: 10.2217/imt-2017-0052.
Abstract
Spurred by the survival benefits seen with the use of checkpoint blockade in non-small-cell lung cancer (NSCLC), there has been a growing interest in the potential applications of immunotherapy. Despite this, the objective response rate for single-agent immunotherapy remains ≤20% in patients with advanced NSCLC. A combinatorial approach that utilizes both chemotherapy and immunotherapy is a potential strategy to increase antitumor efficacy. Accumulating evidence has shown that the immunomodulatory effects of chemotherapeutic agents can be exploited in a combinational approach. Herein, we review the influence of specific chemotherapeutic agents on the tumor immune microenvironment in preclinical and clinical studies, and establish the rationale for combination chemoimmunotherapy for the treatment of NSCLC.
摘要
受非小细胞肺癌（NSCLC）中使用检查点阻断所带来的生存益处的推动，人们对免疫疗法的潜在应用越来越感兴趣。尽管如此，晚期NSCLC患者中单一药物免疫疗法的客观缓解率仍≤20%。将化疗和免疫疗法结合使用的联合方法是提高抗肿瘤疗效的潜在策略。越来越多的证据表明，化疗药物的免疫调节作用可用于联合治疗方法。在此，我们回顾了临床前和临床研究中特定化疗药物对肿瘤免疫微环境的影响，并确立了联合化疗免疫疗法治疗NSCLC的理论依据。
相似文献
1
Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.化疗诱导的非小细胞肺癌免疫调节：联合化疗免疫疗法的理论依据
Immunotherapy. 2017 Sep;9(11):913-927. doi: 10.2217/imt-2017-0052.
2
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.免疫检查点抑制剂联合化疗治疗非小细胞肺癌的分子基础和原理。
Drug Resist Updat. 2019 Sep;46:100644. doi: 10.1016/j.drup.2019.100644. Epub 2019 Sep 17.
3
Lung cancer: potential targets for immunotherapy.肺癌：免疫治疗的潜在靶点。
Lancet Respir Med. 2013 Sep;1(7):551-63. doi: 10.1016/S2213-2600(13)70159-0. Epub 2013 Aug 23.
4
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.明智选择非小细胞肺癌（NSCLC）一线免疫治疗：该加什么，该弃什么。
Cancer Treat Rev. 2019 May;75:39-51. doi: 10.1016/j.ctrv.2019.03.004. Epub 2019 Mar 28.
5
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.非小细胞肺癌中免疫逃逸机制及检查点抑制剂的现状
Cancer Med. 2016 Sep;5(9):2567-78. doi: 10.1002/cam4.819. Epub 2016 Jul 15.
6
Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.免疫检查点阻断作为非小细胞肺癌的潜在治疗靶点。
Expert Opin Biol Ther. 2016 Oct;16(10):1209-23. doi: 10.1080/14712598.2016.1214265. Epub 2016 Aug 5.
7
Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.癌症免疫疗法：治疗非小细胞肺癌的未来范式转变。
Clin Cancer Res. 2015 Mar 1;21(5):976-84. doi: 10.1158/1078-0432.CCR-14-1187.
8
The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.联合免疫疗法作为非小细胞肺癌一线治疗方法的应用。
Future Oncol. 2018 Feb;14(3):191-194. doi: 10.2217/fon-2017-0124. Epub 2018 Jan 16.
9
Targeting Immunometabolism Mediated by CD73 Pathway in -Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.针对 CD73 通路介导的 - 突变型非小细胞肺癌的免疫代谢靶向治疗：克服免疫耐药性的新希望。
Front Immunol. 2020 Jul 14;11:1479. doi: 10.3389/fimmu.2020.01479. eCollection 2020.
10
Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.肺癌的免疫检查点抑制剂治疗：新型药物、生物标志物和治疗模式。
Future Oncol. 2016 Feb;12(4):551-64. doi: 10.2217/fon.15.309. Epub 2016 Jan 18.
引用本文的文献
1
The enhanced pathological response from additional immunotherapy improved recurrence-free survival for esophageal squamous cell carcinoma: a multi-center cohort study.额外免疫治疗增强的病理反应改善了食管鳞状细胞癌的无复发生存率：一项多中心队列研究。
Surg Endosc. 2025 Aug 25. doi: 10.1007/s00464-025-12107-3.
2
Chemotherapy efficacy in advanced melanoma patients after failure of immune checkpoint and BRAF/MEK inhibitors.免疫检查点和BRAF/MEK抑制剂治疗失败后晚期黑色素瘤患者的化疗疗效
Contemp Oncol (Pozn). 2025;29(2):165-170. doi: 10.5114/wo.2025.150451. Epub 2025 May 9.
3
Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy.免疫检查点的翻译后修饰：开启癌症免疫治疗的新潜力。
Exp Hematol Oncol. 2025 Mar 14;14(1):37. doi: 10.1186/s40164-025-00627-6.
4
Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision Medicine.非小细胞肺癌中细胞毒性药物精准给药的机遇：弥合精准医学的差距
Clin Pharmacokinet. 2025 Apr;64(4):511-531. doi: 10.1007/s40262-025-01492-6. Epub 2025 Mar 5.
5
Association of baseline plasma D-dimer and platelets with progression-free survival in patients with stage IV non-small cell lung cancer treated with anti-PD-1 antibody.IV期非小细胞肺癌患者接受抗PD-1抗体治疗时，基线血浆D-二聚体和血小板与无进展生存期的关联
Transl Lung Cancer Res. 2024 Nov 30;13(11):3106-3121. doi: 10.21037/tlcr-24-763. Epub 2024 Nov 28.
6
Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.晚期黑色素瘤患者对抗程序性死亡蛋白1（PD-1）抑制剂耐药后的每周卡铂联合紫杉醇化疗：一项回顾性单中心研究经验
BMC Cancer. 2024 Oct 1;24(1):1220. doi: 10.1186/s12885-024-12961-9.
7
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial.阿维鲁单抗联合洛拉替尼或克唑替尼治疗既往接受过治疗的晚期非小细胞肺癌患者：JAVELIN Lung 101试验1b/2期结果
JTO Clin Res Rep. 2024 May 16;5(7):100685. doi: 10.1016/j.jtocrr.2024.100685. eCollection 2024 Jul.
8
The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort.替莫唑胺和 PD-1/L1 抑制剂在预处理 NSCLC 伴脑转移中的疗效和安全性：回顾性队列研究。
J Cancer Res Clin Oncol. 2024 May 23;150(5):271. doi: 10.1007/s00432-024-05808-0.
9
First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study.一线阿维鲁单抗联合化疗治疗晚期实体瘤患者：来自 Ib/II 期 JAVELIN 化疗联合研究的结果。
Cancer Res Commun. 2024 Jun 28;4(6):1609-1619. doi: 10.1158/2767-9764.CRC-23-0459.
10
Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies.肿瘤内注射大表面积微粒紫杉烷类药物治疗癌症可增加免疫效应细胞浓度、检查点表达，并增强与检查点抑制剂的协同作用：临床前和临床研究综述
Oncol Ther. 2024 Mar;12(1):31-55. doi: 10.1007/s40487-024-00261-y. Epub 2024 Jan 30.
本文引用的文献
1
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.非小细胞肺癌临床实践指南（2017 年第 5 版），NCCN 肿瘤学临床实践指南
J Natl Compr Canc Netw. 2017 Apr;15(4):504-535. doi: 10.6004/jnccn.2017.0050.
2
Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.纳米白蛋白结合型紫杉醇的巨胞饮作用驱动胰腺癌中的巨噬细胞活化。
Cancer Immunol Res. 2017 Mar;5(3):182-190. doi: 10.1158/2326-6066.CIR-16-0125. Epub 2017 Jan 20.
3
Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016.2016年卡诺夫斯基奖：肺癌历程，1973年至2016年
J Clin Oncol. 2017 Jan 10;35(2):243-252. doi: 10.1200/JCO.2016.70.4064. Epub 2016 Nov 7.
4
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
5
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
6
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.卡铂和培美曲塞联合或不联合帕博利珠单抗用于晚期非鳞状非小细胞肺癌：开放标签KEYNOTE-021研究的随机2期队列研究
Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.
7
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
8
Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer.吉西他滨可减少胰腺癌患者的髓源性抑制细胞（MDSCs）、调节性T细胞（Tregs）和转化生长因子β-1（TGFβ-1），同时恢复效应性T细胞/调节性T细胞比例。
J Transl Med. 2016 Sep 29;14(1):282. doi: 10.1186/s12967-016-1037-z.
9
Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells.顺铂诱导的肿瘤消除作用是通过 CD80/86 共刺激 CD8+ T 细胞实现的。
Cancer Res. 2016 Oct 15;76(20):6017-6029. doi: 10.1158/0008-5472.CAN-16-0881. Epub 2016 Aug 28.
10
The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.在肌层浸润性膀胱尿路上皮癌患者中，CD8与调节性T细胞肿瘤浸润淋巴细胞的比例与基于顺铂的新辅助化疗的反应相关。
Oncoimmunology. 2016 Feb 18;5(5):e1134412. doi: 10.1080/2162402X.2015.1134412. eCollection 2016 May.
Zotero 插件